Key result
Targeting mitochondrial dysfunction may reduce atrial fibrillation risk by improving cellular energetics.
Why the study?
The pathomechanisms of atrial fibrillation and its prevention methods remain incompletely understood, and the specific significance of mitochondrial dysfunction in its pathogenesis is not fully elucidated.
Mitochondrial dysfunction contributes to the electrical instability and remodeling in atrial fibrillation, presenting a potential target for pharmacological intervention.
Answers are grounded in this paper and cite their sources.
Mitochondrial-targeted agents merit exploration in AF; leaves open clinical adoption until RCTs confirm benefit and safety.
Despite the enormous progress in the treatment of atrial fibrillation, mainly with the use of invasive techniques, many questions remain unanswered regarding the pathomechanism of the arrhythmia and its prevention methods. The development of atrial fibrillation requires functional changes in the myocardium that result from disturbed ionic fluxes and altered electrophysiology of the cardiomyocyte. Electrical instability and electrical remodeling underlying the arrhythmia may result from a cellular energy deficit and oxidative stress, which are caused by mitochondrial dysfunction. The significance of mitochondrial dysfunction in the pathogenesis of atrial fibrillation remains not fully elucidated; however, it is emphasized by the reduction of atrial fibrillation burden after therapeutic interventions improving the mitochondrial welfare. This review summarizes the mechanisms of mitochondrial dysfunction related to atrial fibrillation and current pharmacological treatment options targeting mitochondria to prevent or improve the outcome of atrial fibrillation.
No takes yet. Share an insight, caveat, or question.
Muszyński et al. (2021) conducted a review in Atrial Fibrillation. Pharmacological interventions targeting mitochondrial dysfunction (e.g., SGLT2 inhibitors, DPP-4 inhibitors, metformin, TZDs) was evaluated. Mitochondrial dysfunction plays a key role in atrial fibrillation pathogenesis, and pharmacological treatments improving mitochondrial function may reduce the risk of arrhythmias.
Synapse has enriched 10 related papers. Consider them for comparative context: